A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder

By Mahableshwarkar Atul R.   Jacobsen Paula L.   Chen Yinzhong  

Current Medical Research and Opinion, Vol. 29, Iss. 3, 2013-03 ,pp. : 217-226

Informa Healthcare

Access to resources Recommend Favorite

Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study

By Nierenberg Andrew A.   Greist John H.   Mallinckrodt Craig H.   Prakash Apurva   Sambunaris Angelo   Tollefson Gary D.   Wohlreich Madelaine M.  

Current Medical Research and Opinion, Vol. 23, Iss. 2, 2007-02 ,pp. : 401-416

Informa Healthcare

Access to resources Recommend Favorite

A comparative study of the efficacy of acute and continuation treatment with escitalopram versus duloxetine in patients with major depressive disorder

By Wade A.   Gembert K.   Florea I.  

Current Medical Research and Opinion, Vol. 23, Iss. 7, 2007-07 ,pp. : 1605-1614

Informa Healthcare

Access to resources Recommend Favorite

A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder

By Colonna Lucien   Andersen Henning Friis   Reines Elin Heldbo  

Current Medical Research and Opinion, Vol. 21, Iss. 10, 2005-10 ,pp. : 1659-1668

Informa Healthcare

Access to resources Recommend Favorite

Randomized, 8‐week, double‐blind, placebo‐controlled trial of vortioxetine in Japanese adults with major depressive disorder, followed by a 52‐week open‐label extension trial

By  

PSYCHIATRY AND CLINICAL NEUROSCIENCES, Vol. 72, Iss. 2, 2018-02 ,pp. : 103-115

John Wiley & Sons Inc

Access to resources Recommend Favorite